Am. J. Respir. Cell Mol. Biol., Volume 26, Number 1, January, 2002 14-21

Timing of Nitric Oxide Donor Supplementation Determines Endothelin-1 Regulation and Quality of Lung Preservation for Transplantation

Kanji Minamoto, David J. Pinsky, Tomoyuki Fujita, and Yoshifumi Naka

Departments of Surgery and Medicine, College of Physicians and Surgeons of Columbia University, New York, New York

Nitroglycerin (NTG) given to donor lungs improves lung preservation for transplantation, but the mechanism(s) underlying this therapeutic benefit remain incompletely understood. Furthermore, it is not known whether the therapeutic window of opportunity for NTG administration is temporally-restricted. Because endothelin-1 (ET-1), a potent vasoconstrictor, and nitric oxide (NO) are reciprocally regulated in vitro, we hypothesized that early administration of the NO donor NTG may suppress ET-1 and thereby improve lung preservation. Using an isogeneic rat left lung transplantation model, four groups were studied (n = 12 transplant/group): (1) NTG given during flush/ preservation (Early NTG); (2) NTG given in the ex vivo flush (Late NTG); (3) No NTG; and (4) a nonselective ET-receptor antagonist (PD156252) given during flush/preservation. Early NTG decreased vascular tone in lung grafts measured ex vivo as well as in vivo following lung transplantation, and resulted in improved survival (100%) and gas exchange (pO₂ 209 ± 19 mm Hg) compared with Late (17%, 62 ± 16 mm Hg) or No NTG (25%, 59 ± 9 mm Hg) (P < 0.05 for Early NTG versus all other groups for both survival and pO₂). PD156252 was associated with an intermediate level of survival (50%) and function (104 ± 23 mm Hg). Transplanted lung graft ET-1 mRNA, measured by Northern blotting and in situ hybridization, and protein, measured by Western blotting and immunohistochemistry, were suppressed only with Early NTG (P < 0.05 versus all other groups). Post-transplantation benefits of NTG are restricted to lung grafts which received NTG during the early harvest and immersion periods, and are coincident with suppression of graft ET-1 expression. When viewed in the context of improved graft survival and function with ET-1 receptor blockade, these data suggest that early administration of NTG to donor lungs improves primary graft function, in part, by suppressing graft ET-1 expression.

This article has been cited by other articles:

				M. Filaire, E. Fadel, B. Decante, F. Seccatore, G.-M. Mazmanian, and P. Herve Inhaled nitric oxide does not prevent postpneumonectomy pulmonary edema in pigs J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 770 - 774. [Abstract] [Full Text] [PDF]

				A. Kher, K. K. Meldrum, M. Wang, B. M. Tsai, J. M. Pitcher, and D. R. Meldrum Cellular and molecular mechanisms of sex differences in renal ischemia-reperfusion injury Cardiovasc Res, September 1, 2005; 67(4): 594 - 603. [Abstract] [Full Text] [PDF]

				R. S Rea, N. T Ansani, and A. L Seybert Role of Inhaled Nitric Oxide in Adult Heart or Lung Transplant Recipients Ann. Pharmacother., May 1, 2005; 39(5): 913 - 917. [Abstract] [Full Text] [PDF]

				T. Wittwer, J. M. Albes, A. Fehrenbach, T. Pech, U. F. W. Franke, J. Richter, and T. Wahlers Experimental lung preservation with Perfadex: Effect of the NO-donor nitroglycerin on postischemic outcome J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1208 - 1216. [Abstract] [Full Text] [PDF]

				M. O. Meade, J. T. Granton, A. Matte-Martyn, K. McRae, B. Weaver, P. Cripps, and S. H. Keshavjee A Randomized Trial of Inhaled Nitric Oxide to Prevent Ischemia-Reperfusion Injury after Lung Transplantation Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1483 - 1489. [Abstract] [Full Text] [PDF]

				Y. Naka Invited Commentary Ann. Thorac. Surg., December 1, 2002; 74(6): 2070 - 2071. [Full Text] [PDF]

				M. R. Karamsetty and J. R. Klinger NO: More Than Just a Vasodilator in Lung Transplantation Am. J. Respir. Cell Mol. Biol., January 1, 2002; 26(1): 1 - 5. [Full Text] [PDF]